These medications are used in combination with personalized care plans that include nutrition counseling, behavioral changes, exercise, handling the root causes of weight gain, and offering long-term solutions
Pathway to Lowest Net Cost Options: Our system is designed to identify the lowest net cost options for the plan sponsor
Selling BPC-157 for human use is against the law
This combination therapy was approved by the US FDA in 2012 for long-term treatment of obesity in adults with a BMI of 30 kg/sq m or a BMI of more than 27 kg/sq m with at least one weight-related disorder
Researchers study this interconnected system to better understand endocrine physiology, receptor communication, and the biological effects of peptide signaling
Phase 5 (Week 17 and beyond): 2.4mg per week The maximum dose used in major clinical research